High Vista Strategies LLC Blueprint Medicines Corp Transaction History

High Vista Strategies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$45.23 - $70.15 $547,644 - $849,376	12,108 New	12,108 $612,000
Q1 2022 May 16, 2022	SELL	$54.1 - $110.08 $748,906 - $1.52 Million	-13,843 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$94.25 - $115.99 $106,219 - $130,720	1,127 Added 8.86%	13,843 $1.48 Million
Q3 2021 Nov 15, 2021	BUY	$80.98 - $109.47 $316,712 - $428,137	3,911 Added 44.42%	12,716 $1.31 Million
Q2 2021 Aug 16, 2021	BUY	$82.78 - $101.0 $728,877 - $889,305	8,805 New	8,805 $774,000
Q3 2020 Nov 16, 2020	SELL	$66.45 - $92.7 $358,564 - $500,209	-5,396 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$57.09 - $79.27 $308,057 - $427,740	5,396 New	5,396 $421,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.